Alistair J. Watt, Ph.D. | March 07, 2017

Validating Flow Cytometry Assays for Immuno-Oncology Trials in the Central Lab

Molecular Medicine Tri-Conference 2017
Presented at Molecular Medicine Tri-Conference 2017, this presentation provides an overview of assay development, validation, and deployment of flow cytometry analysis in immuno-oncology trials. With the expansion of immuno-oncology pipelines, flow cytometry has become a key tool for drug developers, offering new opportunities for immune characterization of samples that can support the development of predictive biomarkers for optimized patient selection, correlation of activation profile to response, and retrospective data analysis. 

Download this presentation to learn how to effectively utilize flow cytometry, following best practices including assay development, validation, technology transfer, instrument standardization, and more. Q2 Solutions is helping its customers effectively utilize flow cytometry services by offering the largest global footprint for flow cytometry services, innovative technology that provides high quality data with minimal variability, and continuous improvement efficiency initiatives to meet customers' individual needs.

Alistair Watt, Ph.D., Director, Translational Science Laboratory, Europe

Related Services:
New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Planning and implementing biomarker testing for immuno-oncology trials

Exploring the challenges with the diverse clinical biomarker requirements

Global Flow Cytometry Services

Unique global flow cytometry services are designed to meet your clinical trial needs

Read More